Nanotechnology Now - Press Release: Emergency Filtration Products Receives Final NanoMask Risk Evaluation Report

Home > Press > Emergency Filtration Products Receives Final NanoMask Risk Evaluation Report

Abstract:
Emergency Filtration Products, Inc. (EFP) (PINKSHEETS: EMFP) today announced that it had received the final NanoMask Risk Evaluation Report.

Emergency Filtration Products Receives Final NanoMask Risk Evaluation Report

LAS VEGAS, NV | Posted on March 3rd, 2008

As previously announced, in 2007 EFP retained internationally recognized experts in the health effects of nanomaterials to evaluate the potential health risk, if any, from use of the company's NanoMask product. Following a thorough review of the medical evidence for nanomaterials in general and the NanoMask in particular, the experts have concluded that "the currently valid scientific evidence demonstrates the absence of unreasonable risk of illness or injury associated with the use of the NanoMask for its intended uses and conditions of use."

"This is a major milestone in our efforts to secure FDA permission to market the NanoMask in the U.S.," said Philip Dascher, CEO, EFP. "Working with emerging technologies, we had to originate new ways to verify the safety and effectiveness of our product, and, as a result this process has taken considerably more time than originally anticipated. However, we are intent on providing all of the information that the FDA has requested with a first-rate scientific basis, even if more time was required."

Mr. Dascher went on to add, "We believe that this expert Risk Evaluation Report eliminates any remaining safety questions. We are now working diligently to complete the other portions of our FDA notification and expect to file it soon."

####

About Emergency Filtration Products, Inc.
EFP was formed to develop a preeminent filtration technology that would serve to ensure the safety of rescuers by virtually eliminating risk of cross-contamination during CPR. Our goal was to elevate the confidence of caregivers to the point where fear of exposure to contagious disease would not cause even a moment's hesitation.

After an extensive period of research and development we were able to achieve two significant early results. The first was 2H Technology™, a unique and highly efficient micro-particle air filter designed for medical filtration, but also suitable and adaptable to a variety of applications outside the medical products industry. The second was the introduction of the first product to utilize this innovative, patented technology, the RespAide® CPR Isolation Mask.

For more information, please click here

Contacts:
Philippe Niemetz
800-477-7570 or 212-344-6464
p.niemetz@panconsultants.com
Investor Relations
PAN Consultants Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: